Ropes & Gray advised Madrigal Pharmaceuticals in an exclusive global license agreement with Pfizer for ervogastat, a Phase 2 oral therapy that could be combined to enhance the clinical effects of Madrigal’s FDA-approved drug Rezdiffra, for treatment of a serious liver disease called metabolic dysfunction-associated steatohepatitis (MASH). The transaction was announced on January 9.
Under the agreement, Madrigal has obtained an exclusive global license to develop, manufacture and commercialize ervogastat and two other early-stage MASH pipeline assets with a $50 million upfront payment to Pfizer. Pfizer is eligible to receive additional payments if certain milestones are achieved, as well as royalties on net sales.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associate Ryan Kramer.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.